Pemetrexed EVER Pharma 25 mg/ml Konzentrat zur Herstellung einer Infusionslösung

DRUG2 trials

Sponsors

Regeneron Pharmaceuticals Inc., Synthekine Inc.

Conditions

Non-small cell lung cancer (NSCLC)Solid Tumours

Phase 1

A Phase 1/2 Study of REGN7075 (EGFRxCD28 Costimulatory Bispecific Antibody) in Combination with Cemiplimab in Patients with Advanced Solid Tumors

RecruitingCTIS2022-501234-37-00

Regeneron Pharmaceuticals Inc.Solid Tumours

Start: 2024-05-07Target: 212Updated: 2025-09-16

Phase 2

A Phase 1/2 Study to Evaluate STK-012 as a Single Agent and in Combination Therapy in Subjects with Front-line Advanced NSCLC and Other Selected Indications

Not yet recruitingCTIS2025-522632-14-00

Synthekine Inc.Non-small cell lung cancer (NSCLC)

Target: 56Updated: 2026-01-13